News &
Media
-
Neurotech International is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment.
View MoreNeurotech is anticipating results from its extended world first study of a medicinal cannabis product in children which could be a game-changer in autism treatment. Read the full story here.
-
ASX Small & Mid-Cap Conference: Neurotech International Limited
View MoreExecutive Director, Dr Tom Duthy presents Neurotech International at the ASX Small and Mid-Cap Conference on the 14th September, 2022. Watch the video recording here.
-
Neurotech International with Proactive at the ASX Small and Mid-Cap Conference
View MoreNeurotech International Executive Director Dr Tom Duthy speaks with Proactive at the ASX Small and Mid-Cap Conference September 2022.
-
Cannabis extract has Autism success
View More
-
New Hope for Children Living with Autism. Channel 7 NEWS 28 August 2022
View More -
Neurotech International appoints industry expert during key phase of growth
View MoreNeurotech International has made key appointments and changes to its board as it focuses on its developing and commercialising neurological solutions, including a cannabis breakthrough for paediatric autism.
-
Gerald Quigley, short discussion on 4RO Rockhampton regarding Autism
View More -
Gerald Quigley, Co-host of The House of Wellness on 6PR discusses exciting new developments in Autism Spectrum Disorder (ASD) field linked to Cannabis, including a particular extract called NTI164.
View More -
Stocks Down Under Interview with Neurotech International (ASX:NTI)
View More